According to DelveInsight, in 2024, Merkel Cell Carcinoma (MCC) accounted for approximately 4,500 cases across the 7MM. The Merkel Cell Carcinoma market is undergoing significant transformation, driven by expanding immunotherapy adoption and a rich clinical pipeline. MCC is highly responsive to radiotherapy, making single-modality radiotherapy viable for inoperable patients, with disease control achieved in 75–85% of cases. Immune checkpoint inhibitors (ICIs) represent the most promising treatment for mMCC. For recurrent skin-site disease, surgery with wider margins remains an option, followed by radiation if not previously administered. While immunotherapy is superior to other modalities in advanced-stage disease, a substantial portion of advanced MCC cases do not respond to PD-1/PD-L1 inhibitors. Approved drugs include BAVENCIO (avelumab), KEYTRUDA (pembrolizumab), and ZYNYZ (retifanlimab-dlwr). In June 2025, the FDA lifted the partial clinical hold on TuHURA Biosciences’ Phase III trial for IFx-2.0, with BLA submission anticipated in H2 2026 and US launch planned for 2027.
Explore DelveInsight’s full Merkel Cell Carcinoma market report for in-depth pipeline, epidemiology, and competitive landscape analysis today.
MCC Key Therapies
- ZYNYZ (retifanlimab-dlwr)
- BAVENCIO (avelumab)
- KEYTRUDA (pembrolizumab)
- IFx-Hu2/IFx-2.0
- BT-001
- MEM-288
- MDNA11
- PH-762
- and others.
MCC Overview
MCC is a rare and aggressive skin cancer originating in Merkel cells located in the epidermis – the skin’s outermost layer. These cells, situated near nerve endings, facilitate touch response. MCC carcinogenesis is associated either with clonally integrated Merkel cell polyomavirus (MCPyV, also known as human polyomavirus HPyV5) or chronic ultraviolet light exposure. Its rarity, aggressive nature, and tendency to metastasize early make it one of the most challenging cutaneous malignancies to manage clinically.
MCC Diagnosis
MCC diagnosis and management requires a coordinated multidisciplinary team including dermatologists, medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, dietitians, and psychiatrists. Given the disease’s rarity and high recurrence risk, psychosocial support for patients and families is strongly recommended.
The primary diagnostic tool is a tissue biopsy. Further staging investigations determine the extent of spread and may include:
- Ultrasound scan
- CT scan
- PET-CT scan
- MRI scan
Accurate staging is essential to guide treatment planning and optimize patient outcomes across all disease stages.
MCC Treatment
Treatment for localized MCC involves wide local excision with or without adjuvant radiotherapy. For metastatic or inoperable disease, immune-based therapies have become the standard of care. Radiotherapy to tumors and/or positive lymph nodes achieves disease control in 75–85% of cases. Post-treatment surveillance requires follow-up every three to six months for the first three years, and every six to twelve months thereafter, with complete skin and lymph node examinations. Imaging may be performed routinely in high-risk patients. Merkel Cell Carcinoma market insight continues to evolve as new data from immunotherapy trials reshape clinical practice. FDA-approved therapies currently include BAVENCIO (avelumab), KEYTRUDA (pembrolizumab), and ZYNYZ (retifanlimab-dlwr).
Merkel Cell Carcinoma (MCC) Epidemiology
DelveInsight’s epidemiology analysis covers the 7MM – the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan – from 2020 to 2034, segmented by total incident cases, gender, age, stage, and treatable cases in first- and second-line settings.
Key epidemiological highlights:
- Germany reported the highest MCC incidence among EU4 and the UK, accounting for approximately 25% of regional cases
- Spain recorded the lowest incidence, representing approximately 15% of EU4 and UK cases
- Approximately 2,500 new MCC cases occur annually within the EU, with around 1,000 patients dying from the disease each year
- Approximately one-third of MCC patients eventually develop distant metastatic disease
- Japan accounted for approximately 500 MCC cases in 2024
Merkel Cell Carcinoma (MCC) Recent Developments
- In September 2025, Merck announced US FDA approval of KEYTRUDA QLEX™ – a subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa – for adults across most solid tumor indications, developed using Alteogen Inc.’s hyaluronidase technology and expected to be available in the US by late September 2025
Leading Merkel Cell Carcinoma Companies
The leading companies developing MCC therapies include Incyte, Merck KGaA (EMD Serono), Merck, TuHURA Biosciences, Transgene and BioInvent, Memgen, Medicenna Therapeutics, Phio Pharmaceuticals, and others advancing candidates across various clinical development stages.
Marketed Drugs
- ZYNYZ (retifanlimab-dlwr) – Incyte
ZYNYZ is an intravenous PD-1 inhibitor approved in March 2023 by the US FDA for adults with recurrent locally advanced or metastatic MCC, under accelerated approval based on tumor response rate and duration of response. Incyte holds global rights to ZYNYZ through an exclusive collaboration and license agreement with MacroGenics.
- BAVENCIO (avelumab) – Merck KGaA (EMD Serono)
BAVENCIO is an anti-PD-L1 antibody that interferes with cancer cell growth and spread. In March 2017, the US FDA granted accelerated approval to BAVENCIO for patients aged 12 years and older with metastatic MCC, based on data from the JAVELIN Merkel 200 trial demonstrating clinically meaningful and durable overall response rates in patients with disease progression following chemotherapy.
Emerging Drugs
- IFx-Hu2/IFx-2.0 – TuHURA Biosciences
IFx-2.0 is a personalized innate immune agonist delivered via intratumoral injection of pDNA encoding an immunogenic bacterial protein, leveraging the patient’s innate immune system to recognize and attack the tumor. In June 2025, TuHURA initiated its Phase III accelerated approval trial for IFx-2.0 in advanced or metastatic MCC following the FDA’s removal of the partial clinical hold. Phase Ib data presented at ASCO 2024 confirmed the therapy was safe and well-tolerated at once-weekly dosing for three weeks. BLA submission is anticipated in H2 2026, with US launch planned for 2027.
- BT-001 – Transgene and BioInvent
BT-001 is an oncolytic vaccinia virus engineered to express GM-CSF and an anti-CTLA-4 antibody, currently in Phase I/II development through a 50/50 collaboration between Transgene and BioInvent. Preliminary data presented at ESMO 2024 showed BT-001, alone or combined with IV pembrolizumab, was well tolerated and demonstrated antitumoral activity, including in PD-(L)1-resistant tumors. Phase I data readout is anticipated in H2 2025.
Merkel Cell Carcinoma (MCC) Market Outlook
Merkel Cell Carcinoma market trends indicate a promising shift toward combination immunotherapy and novel immune-based approaches. Immunotherapy has improved patient outcomes by delivering durable responses in advanced MCC, similar to recent breakthroughs in melanoma treatment. Local radiation therapy has demonstrated an ability to augment immunotherapy responses even at distant tumor sites – a phenomenon known as the abscopal effect. Additionally, MCPyV antibody monitoring is improving recurrence detection and disease surveillance.
Key pipeline findings shaping the Merkel Cell Carcinoma market:
- In April 2025, a Safety Monitoring Committee recommended dose-escalation for a Phase Ib trial of PH-762 (NCT06014086) in MCC, melanoma, and cutaneous squamous cell carcinoma
- In January 2025, Phio Pharmaceuticals reported promising results from its PH-762 clinical study, with two patients achieving complete response and 100% tumor clearance
- In June 2024, TuHURA Biosciences and Kintara Therapeutics announced positive primary analysis results from the Phase Ib IFx-2.0 trial in advanced MCC patients with primary resistance to ICIs
- In April 2024, Kintara Therapeutics and TuHURA Biosciences entered into a Definitive Merger Agreement
Merkel Cell Carcinoma (MCC) Drug Uptake
Drug uptake analysis for the 2020–2034 forecast period evaluates the adoption trajectory of potential therapies based on the competitive landscape, clinical safety and efficacy profiles, and order of market entry. Key players advancing novel therapies through pivotal and confirmatory trials must carefully select appropriate comparators to maximize the likelihood of regulatory approval, ensure smooth market launches, and support rapid real-world uptake across the 7MM.
Download the comprehensive Merkel Cell Carcinoma market research report and gain strategic insights to navigate this evolving oncology landscape now.
Conclusion
The Merkel Cell Carcinoma market is poised for substantial growth through 2034, driven by rising disease awareness, improved diagnostic practices, and rapid advancements in immunotherapy-based treatments. FDA-approved therapies such as BAVENCIO, KEYTRUDA, and ZYNYZ have significantly transformed the treatment landscape, while emerging candidates including IFx-2.0, BT-001, MDNA11, and PH-762 are expected to further expand therapeutic possibilities. Increasing research into combination therapies, viral-targeted strategies, and personalized immuno-oncology approaches is strengthening the clinical pipeline. With ongoing regulatory progress, robust epidemiological trends, and expanding investment from leading oncology companies, the MCC market is expected to witness continued innovation, competitive expansion, and improved patient outcomes worldwide.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
